The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

Thunnissen, Erik; Kerr, Keith M.; Herth, Felix; Lantuéjoul, Sylvie; Papotti, Mauro; Rintoul, Robert C.; Rossi, Giulio; Skov, Birgit B.G.; Weynand, Birgit; Bubendorf, Lukas; Grünberg, Katrien; Johansson, Leif; López‐Ríos, Fernando; Ninane, Vincent; Olszewski, Włodzimierz; Popper, Helmut; Jaume, Sauleda; Schnabel, Philipp A.; Thiberville, Luc; Laenger, Florian

doi:10.1016/j.lungcan.2011.10.017

Cited by 204 publications

(236 citation statements)

References 226 publications

(299 reference statements)

Supporting

Mentioning

223

Contrasting

Unclassified

Order By: Relevance

“…The diagnostic steps in NSCLC comprise establishing the presence of malignancy, identifying the type of malignancy, and performing predictive testing through biomarker identification [6,13]. In the first instance, malignancy should be identified by light microscopic examination using routine and special stains (including haematoxylin and eosin [H&E], mucin stains and various cytological stains) [13].…”

Section: Diagnostic Steps In Nsclcmentioning

confidence: 99%

“…In the first instance, malignancy should be identified by light microscopic examination using routine and special stains (including haematoxylin and eosin [H&E], mucin stains and various cytological stains) [13].…”

Section: Diagnostic Steps In Nsclcmentioning

confidence: 99%

“…Distinguishing between small cell lung cancer (SCLC) and NSCLC then follows, based upon morphology [13]. Knowledge of clinical history is essential to assess the possibility of metastatic disease to the lung and should be considered in combination with the morphological appearance of the tumour.…”

Section: Diagnostic Steps In Nsclcmentioning

confidence: 99%

“…However, resources should not be wasted in an inappropriate pursuit to differentiate primary from secondary tumours in the lung, and accordingly, good communication between clinician and pathologist is imperative. In the majority of NSCLC cases, morphological examination alone can accurately subtype NSCLC as squamous or adenocarcinoma [13], without a need for immunohistochemistry (IHC), thus preserving tissue for later molecular testing. However, approximately one third of tumours identified in small samples will exhibit no specific, morphological evidence of either adenocarcinoma or squamous cell carcinoma (NSCLC-NOS) [14,15].…”

Section: Diagnostic Steps In Nsclcmentioning

confidence: 99%

“…Studies evaluating IHC markers have demonstrated that a marker panel comprising TTF-1, p63, CK5/6 and CK7 is the most robust compromise for NSCLC subtyping, particularly when tissue is limited [15,18,19]. Immunophenotyping of NSCLC should therefore be limited to between 2 and 4 markers [13]. Moreover, Napsin A is not thought to yield additional information beyond that provided by TTF-1, [13] but may be useful when TTF-1 staining is equivocal [18].…”

Section: Diagnostic Steps In Nsclcmentioning

confidence: 99%

See 4 more Smart Citations

Diagnosis and Predictive Molecular Analysis of Non–Small-Cell Lung Cancer in the Africa-Middle East Region: Challenges and Strategies for Improvement

Slavík

Asselah

Fakhruddin

et al. 2014

Clinical Lung Cancer

Self Cite

View full text Add to dashboard Cite

Identification of tumour biomarkers provides information on prognosis and guides the implementation of appropriate treatment in patients with many different types of cancer. In nonsmall-cell lung cancer (NSCLC), targeted treatment plans based on biomarker identification are already being utilised in the clinic. However, such predictive molecular testing is not currently a universally employed practice. This is particularly the case in developing countries where lung cancer is increasingly prevalent. In September 2012 and November 2013, a committee of 16 lung cancer experts from Africa and the Middle East met to discuss key issues related to diagnosis and biomarker testing in NSCLC and the implementation of personalised medicine in the region. The committee identified current challenges for effective diagnosis and predictive analysis in Africa and the Middle East. Moreover, strategies to encourage the implementation of biomarker testing were discussed.Ultimately, a practical approach for the effective diagnosis and predictive molecular testing of NSCLC in these regions was derived. Key issues and recommendations arising from the meetings are presented here.Abstract word count: 167 (journal limit: 250)

show abstract

Section: Diagnostic Steps In Nsclcmentioning

confidence: 99%

Section: Diagnostic Steps In Nsclcmentioning

confidence: 99%

Section: Diagnostic Steps In Nsclcmentioning

confidence: 99%

Section: Diagnostic Steps In Nsclcmentioning

confidence: 99%

Section: Diagnostic Steps In Nsclcmentioning

confidence: 99%

See 3 more Smart Citations

Diagnosis and Predictive Molecular Analysis of Non–Small-Cell Lung Cancer in the Africa-Middle East Region: Challenges and Strategies for Improvement

Slavík

Asselah

Fakhruddin

et al. 2014

Clinical Lung Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective

Misra

Singh

2019

Cancer Medicine

View full text Add to dashboard Cite

Lung cancer is the leading cause of deaths related to cancer and accounts for more than a million deaths per year. Various new strategies have been developed and adapted for treatment; still the survival for 5 years is just 16% in patients with non‐small cell lung cancer (NSCLC). Most of these strategies to combat NSCLC whether it is a drug molecule or immunotherapy/vaccine candidate require a big cost and time. Integration of computational modeling with systems biology has opened new avenues for understanding complex cancer biology. Resolving the complex interactions of various pathways and their crosstalk leading to oncogenic changes could identify new therapeutic targets with lesser cost and time. Herein, this review provides an overview of various aspects of NSCLC along with available strategies for its cure concluding with our insight into how systems approach could serve as a therapeutic intervention dissecting the immunologic parameters and cross talk between various pathways involved.

show abstract

Factors affecting the success of next‐generation sequencing in cytology specimens

Roy‐Chowdhuri

Goswami

Chen

et al. 2015

Cancer Cytopathology

135

171

View full text Add to dashboard Cite

BACKGROUND:The use of cytology specimens for next-generation sequencing (NGS) is particularly challenging because of the unconventional substrate of smears and the often limited sample volume. An analysis of factors affecting NGS testing in cytologic samples may help to increase the frequency of successful testing. METHODS: This study reviewed variables associated with all in-house cytology cases (n 5 207) that were analyzed by NGS with the Ion Torrent platform during a 10-month interval. A statistical analysis was performed to measure the effects of the DNA input threshold, specimen preparation, slide type, tumor fraction, DNA yield, and cytopathologist bias. RESULTS: One hundred sixty-four of 207 cases (79%) were successfully sequenced by NGS; 43 (21%) failed because of either a low DNA yield or a template/library preparation failure. The median estimated tumor fraction and DNA concentration for the successfully sequenced cases were 70% and 2.5 ng/lL, respectively, whereas they were 60% and 0.2 ng/lL, respectively, for NGS failures. Cell block sections were tested in 91 cases, and smears were used in 116 cases. NGS success positively correlated with the DNA yield but not the tumor fraction. Cell block preparations showed a higher success rate than smears. Frosted-tip slides yielded significantly more DNA than fully frosted slides. Lowering the input DNA concentration below the manufacturer's recommended threshold of 10 ng (>0.85 ng/lL) resulted in a marked increase in the NGS success rate from 58.6% to 89.8%. CONCLUSIONS:The failure of NGS with cytology samples is usually a result of suboptimal DNA due to multiple pre-analytical factors.Knowledge of these factors will allow better selection of cytology material for mutational analysis. Cancer (Cancer Cytopathol) 2015;123:659-68.

show abstract

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

Cited by 204 publications

References 226 publications

Diagnosis and Predictive Molecular Analysis of Non–Small-Cell Lung Cancer in the Africa-Middle East Region: Challenges and Strategies for Improvement

Diagnosis and Predictive Molecular Analysis of Non–Small-Cell Lung Cancer in the Africa-Middle East Region: Challenges and Strategies for Improvement

Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective

Factors affecting the success of next‐generation sequencing in cytology specimens

Contact Info

Product

Resources

About